substituted or unsubstituted C_2-C_6-alkenyl, substituted or unsubstituted C_2-C_6-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C_1-C_6-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, acyloxy, acylamino, sulfoxy, sulfonyl, substituted or unsubstituted C_1-C_6- thioalkoxy.

5. (Amended) A sulfonyl amino acid derivative according to claim 1, wherein at least one of R^3 and/or R^4 is selected from the group consisting of the following natural amino acid residues : alanyl, arginyl, asparaginyl, aspartyl, cysteinyl, glutaminyl, glutamyl, glycyl, histidyl, isoleucyl, leucyl, lysyl, methionyl, phenylalanyl, prolyl, seryl, threonyl, tryptophanyl, tyrosyl, valyl.

6. (Amended) A sulfonyl amino acid derivative according to claim 1, wherein

Ar^1 is an unsubstituted or substituted phenyl, preferably 4-chlorophenyl, X is O, R^1, R^2, R^3 and R^4 are hydrogen, n is 1, Ar^2 is thienyl, R^5 is H or C_1-C_6-alkyl;

R^6 is selected from the group comprising or consisting of H, a substituted or unsubstituted C_1-C_6-aliphatic alkyl - e.g. a C_1-C_6-alkylamino aryl, a C_1-C_6-alkylamino heteroaryl, a substituted or unsubstituted cyclic C_4-C_8-alkyl containing optionally 1-3 heteroatoms and being optionally fused with an unsubstituted or substituted aryl or heteroaryl; or R^6 is an unsubstituted or substituted aryl or heteroaryl;

said aryl or heteroaryl groups are optionally substituted by substituted or unsubstituted C_1-C_6-alkyl, like trihalomethyl, substituted or unsubstituted C_1-C_6-alkoxy, substituted or unsubstituted C_2-C_6-alkenyl, substituted or unsubstituted C_2-C_6-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C_1-C_6-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, C_1-C_6- thio alkoxy; or

R^5 and R^6 taken together could form an unsubstituted or substituted 4-8-membered saturated cyclic alkyl or heteroalkyl group, e.g. an unsubstituted or substituted piperidino group.

7. (Amended) A sulfonyl amino acid derivative according to claim 1, wherein R^5 is H; and R^6 is a C_1-C_6-alkyl which is substituted by an aryl, an heteroaryl group or an aminoaryl, aminoheteroaryl, aryloxy, heteroaryloxy, whereby said aryl and heteroaryl groups are optionally substituted by substituted or unsubstituted C_1-C_6-alkyl, like trihalomethyl, substituted or unsubstituted C_1-C_6-alkoxy, substituted or unsubstituted C_2-C_6-alkenyl, substituted or unsubstituted C_2-C_6-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C_1-C_6-alkoxycarbonyl, substituted or unsubstituted aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, C_1-C_6-thioalkoxy.

9. (Amended) A sulfonyl amino acid derivative according to claim 1 ~~which is~~ selected from the following group :

4-chloro-N-({5-[({2-[(2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]-2-oxoethyl}amino)sulfonyl]thien-2-yl}methyl)benzamide

4-chloro-N-[(5-{[(2-{[2-({5-nitropyridin-2-yl}amino)ethyl]amino}-2-oxoethyl)-amino]sulfonyl}thien-2-yl)methyl]benzamide

4-chloro-N-({5-[({2-oxo-2-[(2-{[3-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]ethyl}amino)sulfonyl]thien-2-yl}methyl)benzamide

4-chloro-N-({5-[({2-oxo-2-[(2-{[5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]ethyl}amino)sulfonyl]thien-2-yl}methyl)benzamide

N-({5-[({2-[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]-2-oxoethyl}amino)-sulfonyl]thien-2-yl}methyl)-4-chlorobenzamide

4-chloro-N-[(5-{[(2-oxo-2-{3-[(trifluoromethyl)sulfonyl]anilino}ethyl)amino]-sulfonyl}thien-2-yl)methyl]benzamide.

12. (Amended) Use according to claim 10 for the treatment or prevention of disorders associated with abnormal expression or activity of JNK2 and/or 3.

13. (Amended) Use of a sulfonyl amino acid derivative according to formula I in particular claim 10 for the treatment of neuronal disorders including epilepsy; Alzheimer's disease, Huntington's disease, Parkinson's disease; retinal diseases, spinal cord injury, head trauma.

14. (Amended) Use of a sulfonyl amino acid derivative according to formula I in particular according to claim 10 for the treatment of autoimmune diseases including Multiple Sclerosis, inflammatory bowel disease (IBD), rheumatoid arthritis, asthma, septic shock, transplant rejection.

A3

15. (Amended) Use of a sulfonyl amino acid derivative according to formula I in particular according to claim 10 for the treatment of cancer including breast-, colorectal-, pancreatic cancer.

16. (Amended) Use of a sulfonyl amino acid derivative according to formula I in particular according to claim 10 for the treatment of cardiovascular diseases including stroke, arterosclerosis, myocordial infarction, myocordial reperfusion injury.

17. (Amended) A pharmaceutical composition containing at least one sulfonyl amino acid derivative according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

18. (Amended) Process for the preparation of a sulfonyl amino acid derivative according to claim 1 comprising or consisting of the steps of:

a) preparing a sulfonyl compound V,



V

b) reacting it with the protected amino acid compound VIII



VIII

thus leading to a compound



IX

A3

c) said compound IX is subjected to a deprotection and finally

d) a coupling.

19. (Amended) Process for the preparation of the sulfonyl amino acid derivatives according to claim 1 comprising or consisting of the steps of:

a) preparing a protected sulfonyl compound VII



VII

b) reacting it with the protected amino acid compound VIII



VIII

thus leading to a compound



X

e) followed by deprotection;

f) coupling;

A3

g) deprotection, and

h) acylation.

Please add the following new claims.

20. (New) A sulfonyl amino acid derivative according to claim 2, wherein n is 1.

21. (New) A sulfonyl amino acid derivative according to claim 2, wherein Ar^1 and Ar^2 are independently selected from the group comprising or consisting of phenyl, thienyl, furyl, pyridyl, said residues being optionally substituted by at least one substituted or unsubstituted C_1-C_6-alkyl, like trihalomethyl, substituted or unsubstituted C_1-C_6-alkoxy, substituted or unsubstituted C_2-C_6-alkenyl, substituted or unsubstituted C_2-C_6-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C_1-C_6-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, acyloxy, acylamino, sulfoxy, sulfonyl, substituted or unsubstituted C_1-C_6- thioalkoxy.

A4

22. (New) A sulfonyl amino acid derivative according to claim 2, wherein at least one of R^3 and/or R^4 is selected from the group consisting of the following natural amino acid residues : alanyl, arginyl, asparaginyl, aspartyl, cysteinyl, glu-taminyl, glutamyl, glycyl, histidyl, isoleucyl, leucyl, lysyl, methionyl, phenylalanyl, prolyl, seryl, threonyl, tryptophanyl, tyrosyl, valyl.

23. (New) A sulfonyl amino acid derivative according to claim 2, wherein

Ar^1 is an unsubstituted or substituted phenyl, preferably 4-chlorophenyl, X is O, R^1, R^2, R^3 and R^4 are hydrogen, n is 1, Ar^2 is thienyl, R^5 is H or C_1-C_6-alkyl;

R^6 is selected from the group comprising or consisting of H, a substituted or unsubstituted C_1-C_6-aliphatic alkyl - e.g. a C_1-C_6-alkylamino aryl, a C_1-C_6-alkylamino

heteroaryl, a substituted or unsubstituted cyclic C_4-C_8-alkyl containing optionally 1-3 heteroatoms and being optionally fused with an unsubstituted or substituted aryl or heteroaryl; or R^6 is an unsubstituted or substituted aryl or heteroaryl;

said aryl or heteroaryl groups are optionally substituted by substituted or unsubstituted C_1-C_6-alkyl, like trihalomethyl, substituted or unsubstituted C_1-C_6-alkoxy, substituted or unsubstituted C_2-C_6-alkenyl, substituted or unsubstituted C_2-C_6-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C_1-C_6-alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, C_1-C_6- thio alkoxy; or

R^5 and R^6 taken together could form an unsubstituted or substituted 4-8-membered saturated cyclic alkyl or heteroalkyl group, e.g. an unsubstituted or substituted piperidino group.

24. (New) A sulfonyl amino acid derivative according to claim 2, wherein

R^5 is H; and R^6 is a C_1-C_6-alkyl which is substituted by an aryl, an heteroaryl group or an aminoaryl, aminoheteroaryl, aryloxy, heteroaryloxy, whereby said aryl and heteroaryl groups are optionally substituted by substituted or unsubstituted C_1-C_6-alkyl, like trihalomethyl, substituted or unsubstituted C_1-C_6-alkoxy, substituted or unsubstituted C_2-C_6-alkenyl, substituted or unsubstituted C_2-C_6-alkynyl, amino, acylamino, aminocarbonyl, substituted or unsubstituted C_1-C_6-alkoxycarbonyl, substituted or unsubstituted aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfoxy, C_1-C_6-thioalkoxy.

25. (New) A sulfonyl amino acid derivative according to claim 24 which is selected from the following group :

4-chloro-N-({5-[({2-[(2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]-2-oxoethyl}amino)sulfonyl]thien-2-yl}methyl)benzamide

4-chloro-N-[(5-{[(2-{[2-({5-nitropyridin-2-yl}amino)ethyl]amino}-2-oxoethyl)-amino]sulfonyl}thien-2-yl)methyl]benzamide

4-chloro-N-({5-[({2-oxo-2-[(2-{[3-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]ethyl}amino)sulfonyl]thien-2-yl}methyl)benzamide

4-chloro-N-({5-[({2-oxo-2-[(2-{[5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]ethyl}amino)sulfonyl]thien-2-yl}methyl)benzamide

N-({5-[({2-[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]-2-oxoethyl}amino)-sulfonyl]thien-2-yl}methyl)-4-chlorobenzamide

4-chloro-N-[(5-{[(2-oxo-2-{3-[(trifluoromethyl)sulfonyl]anilino}ethyl)amino]-sulfonyl}thien-2-yl)methyl]benzamide.

26. (New) A pharmaceutical composition containing at least one sulfonyl amino acid derivative according to claim 2 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

27. (New) Process for the preparation of a sulfonyl amino acid derivative according to claim 2 comprising or consisting of the steps of:

a) preparing a sulfonyl compound V,



V

b) reacting it with the protected amino acid compound VIII



VIII

thus leading to a compound



IX

c) said compound IX is subjected to a deprotection and finally

d) a coupling.

28. (New) Process for the preparation of the sulfonyl amino acid derivatives according to claim 2 comprising or consisting of the steps of:

a) preparing a protected sulfonyl compound VII



VII

b) reacting it with the protected amino acid compound VIII



VIII

thus leading to a compound



X

e) followed by deprotection;

f) coupling;

g) deprotection, and

h) acylation.